Given that targeted CGRP therapies likely have a significant peripheral effect at the level of the trigeminal ganglion and represent the current state of the art therapeutics for migraine (Ong, Wei, & Goadsby, 2018), we propose herein that ASIC3 blockade may represent a potential adjunct target for reducing CGRP release. This evidence concerns the gene ASIC3 and migraine disorder.